NEOGAP Therapeutics AB-preview

Neogap

NEOGAP Therapeutics AB

Private

StockholmHealthcare & Life Scienceshttps://neogap.se

Last Round

Early Funding

Feb 11, 2026

Total Funding Raised

$19.44M

Company Overview

NEOGAP Therapeutics AB is a biotechnology company that develops personalized cancer immunotherapy designed to precisely target and eliminate cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

pTTLpersonalized immunotherapyadoptive cell therapysolid tumor therapycancer immunotherapyneoantigen selectionT-cell therapyT-cell expansionpersonalised tumour trained lymphocytesautologous cell therapycolorectal cancer treatmentimmuno-oncologyprecision oncologyPIOREpiTCerneoantigen selection softwarebiotech licensingclinical-stage biopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NEOGAP Therapeutics AB Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NEOGAP Therapeutics AB Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Feb 11, 2026
Grant	Nov 5, 2025
Grant	Feb 26, 2025
Grant	Mar 26, 2024
Private Placement	Nov 9, 2023
Grant	Nov 9, 2023

View all Funding Rounds

Key People

Founding team and executive leadership

Samuel Svensson

CEO

Executive Team

Guro Gafvelin

Chief Technology Officer

Executive Team

Andrea Salmén

Chief Operating Officer

Executive Team

NEOGAP Therapeutics AB Investors

Notable investors and investment history

Investor	Rounds
European Innovation Council	Grant
Vinnova	Grant
Sciety	Series A, Early Funding, Private Placement

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Feb 11, 2026
Raised $9.8M in early funding.
Feb 11, 2026
Partnered with NorthX Biologics to advance cell therapy manufacturing.

View all signals

NEOGAP Therapeutics AB Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

NEOGAP Therapeutics AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NEOGAP Therapeutics AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersStockholm

Employee Range25

Year Founded2016

Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.